I am Sohta Yamaguchi, President and Representative Director of ASKA Pharmaceutical Co., Ltd.
I would like to express my sincere appreciation to all our stakeholders for their continued support of our group’s business activities.
The environment surrounding the domestic ethical pharmaceutical business continues to become increasingly challenging due to factors such as Japan’s declining birthrate and aging population, as well as ongoing revisions to the drug pricing system driven by efforts to control social security costs. On the other hand, there is a growing societal interest across the entire healthcare continuum, including prevention, testing and diagnosis, treatment, and prognosis.
Under these circumstances, our group has been implementing the Mid-Term Management Plan 2025 since FY2021, working toward becoming a “Total Healthcare Company” with a strong foundation as a specialty pharma company. As a result, in the final year of the plan, we achieved net sales of ¥71.1 billion, an operating profit margin of 8.2%, and an ROE of 8.0%, successfully accomplishing all of our numerical targets.
Since its founding in 1920, ASKA Pharmaceutical has been committed to creating innovative pharmaceuticals that address medical needs, guided by our corporate philosophy: “Contribute toward the improvement of people's health and progress in medicine through the development of innovative products.”
Currently, we are focusing on three key therapeutic areas—obstetrics and gynecology, internal medicine (gastroenterology and thyroid), and urology—and are strengthening our competitiveness as a Specialty Healthcare Company by promoting the development of new drugs to address unmet medical needs.
Looking ahead, under our long-term vision “ASKA VISION 2035,” we will pursue sustainable growth by further strengthening our drug discovery and promoting global expansion.
Building on the drug discovery capabilities we have cultivated since our founding, we will continue to take on new challenges in response to the rapidly changing business environment and strive to create lasting value for all our stakeholders.
We appreciate your continued understanding and support.
Sohta Yamaguchi
President, Member of the Board of Directors, Representative Director